Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metamizole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | BCHE | P06276 | 7/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metamizole SCHEMBL27828487 | 0.99 | PTGS1 (0.97) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL867884 | 0.99 | PTGS1 (0.97) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL27598082 | 0.99 | PTGS1 (0.97) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL16823495 | 0.97 | PTGS1 (0.95) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL867882 | 0.97 | PTGS1 (0.95) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| SCHEMBL13524328 | 0.90 | PTGS1 (0.81) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| SCHEMBL13524335 | 0.88 | PTGS1 (0.78) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| SCHEMBL27870014 | 0.86 | PTGS1 (0.75) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL24996 | 0.86 | ALOX15 (1.00) | PTGS1ALOX15KDM4EMAPTALOX12 | |
| Metamizole SCHEMBL24995 | 0.85 | ALOX15 (0.97) | PTGS1ALOX15KDM4EMAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083666-A1 | METHOD OF TREATING DISEASE | CREWS THOMAS M (US) | 2026-03-26 | — | — | US | claimed |
| US-12427532-B2 | Magnetic levitation system | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-09-30 | — | — | US | claimed |
| EP-4554594-A1 | METHODS OF ADMINISTERING BELUMOSUDIL IN COMBINATION WITH CYP3A INDUCERS AND/OR PROTON PUMP INHIBITORS | Kadmon Corporation, LLC (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2025068949-A1 | EMRUSOLMIN FOR USE IN TREATING MULTIPLE SYSTEM ATROPHY | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2025-04-03 | — | — | WO | claimed |
| US-20250099590-A1 | HIGH DENSITY ULTRASOUND COUPLING GEL AND METHODS OF USE THEREOF | ZETROZ SYSTEMS LLC (US) | 2025-03-27 | — | — | US | claimed |
| WO-2024224329-A1 | COMPOSITIONS COMPRISING A CANNABINOID AND A NON-CANNABINOID, NON-TERPENE COMPOUND | BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| US-20240269115-A1 | PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES | FLONEXT S.R.L. (IT) | 2024-08-15 | — | — | US | claimed |
| EP-4371563-A1 | COMBINATIONS OF LAROTRECTINIB AND MODERATE CYP3A4 INDUCERS | Bayer Consumer Care AG (CH) | 2024-05-22 | — | — | EP | claimed |
| EP-4351571-A1 | PYRAZOLONE COMPOUNDS FOR USE IN DEGENERATIVE RETINAL DISEASES | Flonext S.r.l. (IT) | 2024-04-17 | — | — | EP | claimed |
| WO-2024052766-A1 | CYTOTOXIC AGENT FOR CHEMICAL DISBUDDING AND METHOD | Welfare Concepts Limited (NZ) | 2024-03-14 | — | — | WO | claimed |
| CN-1089495-A | Fever-reducing suppository for children and preparation method thereof | BEIFANG PHARMACEUTICAL FACTORY (CN) | 1994-07-20 | — | — | CN | claimed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0467978-A4 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | — | 1992-03-11 | — | — | EP | claimed |
| EP-0467978-A1 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | ENZYMATICS, INC. (US) | 1992-01-29 | — | — | EP | claimed |
| EP-0311616-B1 | COMBINATIONS OF GAMMA INTERFERONS AND ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENTS FOR TREATING DISEASES | BIOGEN NV (NL) | 1991-09-25 | — | — | EP | claimed |
| WO-1990012113-A1 | THE USE OF FLUID INSOLUBLE OXIDIZING AGENTS TO ELIMINATE INTERFERING SUBSTANCES IN OXIDATION-REDUCTION MEASURING SYSTEMS | ENZYMATICS, INC. (US) | 1990-10-18 | — | — | WO | claimed |
| EP-0311616-A4 | COMBINATIONS OF GAMMA INTERFERONS AND ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENTS FOR TREATING DISEASES. | BIOGEN NV (NL) | 1989-05-23 | — | — | EP | claimed |
| EP-0311616-A1 | COMBINATIONS OF GAMMA INTERFERONS AND ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENTS FOR TREATING DISEASES. | BIOGEN NV (NL) | 1989-04-19 | — | — | EP | claimed |
| WO-1987007842-A1 | COMBINATIONS OF GAMMA INTERFERONS AND ANTI-INFLAMMATORY OR ANTI-PYRETIC AGENTS AND METHODS FOR TREATING DISEASES | BIOGEN N.V. (AN) | 1987-12-30 | — | — | WO | claimed |
| US-4699776-A | Suppositories containing analgesics, antipyretics or anti-inflammatory agents | R. P. SCHERER CORPORATION (US) | 1987-10-13 | — | — | US | claimed |